Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Risuteganib - Allegro Ophthalmics

Next Previous
Drug Profile

Risuteganib - Allegro Ophthalmics

Alternative Names: ALG-1001; AM-011; Integrin Peptide Therapy; Luminate

Latest Information Update: 03 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Allegro Ophthalmics
  • Developer Allegro Ophthalmics; Hanmi Pharmaceutical
  • Class Amides; Anti-inflammatories; Carboxylic acids; Eye disorder therapies; Guanidines; Neuroprotectants; Oligopeptides; Pyrrolidines
  • Mechanism of Action Integrin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Dry age-related macular degeneration
  • No development reported Diabetic macular oedema; Diabetic retinopathy; Retinal disorders; Wet age-related macular degeneration
  • Discontinued Retinitis pigmentosa

Most Recent Events

  • 03 Aug 2026 Discontinued - Phase-I for Retinitis pigmentosa in South Korea (Intravitreous) (Hanmi Pharmaceutical pipeline, August 2026)
  • 03 Aug 2026 No development reported - Phase-II for Diabetic macular oedema (Adjunctive treatment) in USA (Intravitreous) (Hanmi Pharmaceutical/AffaMed Therapeutics Pipeline, August 2026)
  • 03 Aug 2026 No development reported - Phase-II for Diabetic macular oedema (Combination therapy) in USA (Intravitreous) (Hanmi Pharmaceutical/AffaMed Therapeutics Pipeline, August 2026)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top